Trial designs and endpoints for immune therapies in multiple myeloma
American Journal of Hematology · 2023-03 · 98 (S2)
DOI: 10.1002/ajh.26753 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 07.11.2022. Verfasst von Guido Lancman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Immunoconjugates. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
Immune therapies, including CAR‐T cells, bispecific antibodies, and antibody‐drug conjugates, are revolutionizing the treatment of multiple myeloma. In this review, we discuss clinical trial design considerations relevant to immune therapies. We first examine issues pertinent to specific populations, including elderly, patients with renal impairment, high‐risk/extramedullary disease, and prior immune therapies. We then highlight trial designs to optimize the selection of dose and schedule, explore rational combination therapies based on preclinical data, and evaluate the nuances of commonly used endpoints. By exploiting their pharmacokinetic/pharmacodynamic profiles and utilizing novel translational insights, we can optimize the use of immune therapies in multiple myeloma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
- Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
ORCID-Profile: Guido Lancman, Shambavi Richard, Joshua Richter
Zitieren
APA
Lancman, G., Moshier, E., Cho, H. J., Parekh, S., Richard, S., Richter, J., Rodriguez, C., Rossi, A., Sanchez, L., Jagannath, S., & Chari, A. (2023). Trial designs and endpoints for immune therapies in multiple myeloma. American Journal of Hematology, 98(S2). https://doi.org/10.1002/ajh.26753
Vancouver
Lancman G, Moshier E, Cho HJ, Parekh S, Richard S, Richter J, et al. Trial designs and endpoints for immune therapies in multiple myeloma. American Journal of Hematology. 2023;98(S2). doi:10.1002/ajh.26753
BibTeX
@article{Lancman2023,
author = {Lancman, Guido and Moshier, Erin and Cho, Hearn Jay and Parekh, Samir and Richard, Shambavi and Richter, Joshua and Rodriguez, Cesar and Rossi, Adriana and Sanchez, Larysa and Jagannath, Sundar and Chari, Ajai},
title = {Trial designs and endpoints for immune therapies in multiple myeloma},
journal = {American Journal of Hematology},
year = {2023},
volume = {98},
number = {S2},
doi = {10.1002/ajh.26753}
}
EUVIMED